Compliant Red Yeast Rice Alternative, ANKASCIN® 568

RED YEAST RICE AT A TURNING POINT Red yeast rice (RYR), produced by fermenting rice with Monascus purpureus, has long been used in traditional practice to support cholesterol management. Its key compound, Monacolin K, inhibits HMG-CoA reductase—the same pathway targeted by statin drugs. However, due to its statin-like activity and potential side effects, Monacolin K faces growing regulatory pressure worldwide, including in the EU and the US. In 2024, the EU tightened restrictions after safety concerns at intake levels as low as 3 mg/day, accelerating the phase-out of traditional monacolin-based red yeast rice as a complete ban is proposed for 2026. ANKASCIN® 568: REIMAGINING RED YEAST RICE ANKASCIN® 568, powered by the patented strain Monascus purpureus NTU 568 and precision solid-state fermentation, reimagines red yeast rice beyond Monacolin K—unlocking a longevity-driven metabolic pathway. Rich in Monascin and Ankaflavin, ANKASCIN® 568 clinically supports key pillars of healthy aging—lipid balance, glucose regulation, and blood pressure management—while enhancing endogenous antioxidant defense. Backed by 130+ SCI publications, it is completely Monacolin K–free and compliant with EU and US regulations, delivering a science-powered and regulation-resilient solution for next-generation cardiovascular health.